TSO3 Inc. announced that TSO3 and a fund (the 'Fund') of which Courage Capital Management LLC, ('Courage') is the investment advisor, have entered into a binding USD 20 million debt financing to fund commercialization initiatives for its STERIZONE VP4 Sterilizer, the only terminal sterilization method that is FDA cleared to sterilize multi-channeled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as certain colonoscopes, gastroscopes and duodenoscopes. Concurrent with the Courage financing, TSO3 and Getinge Infection Control AB ('Getinge') mutually decided not to renew the distribution agreements between the parties, and have agreed to provide TSO3 unrestricted independent commercialization of its STERIZONE VP4 Sterilizers; the company's purchase of approximately 230 STERIZONE VP4 Sterilizers, 220 of which are from Getinge's inventory, for $33,000 per sterilizer; transfer Getinge's existing sales pipeline to TSO3 in exchange for shared economics at the completion of sale and 4) transition to TSO3 the service, maintenance and consumables sales of all existing STERIZONE VP4 Sterilizer customers in the United States and Canada. Getinge and TSO3 envision maintaining an ongoing collaborative relationship where TSO3 supplies and supports the STERIZONE VP4 Sterilizer to satisfy Getinge customers looking for a total sterilization solution.